Author

F. Magrangeas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:statistical model· 4 Research Focus:chromatin & epigenetic regulation· 3 Assay:DNA methylation· 2 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:clustering· 1

Frequent Co-Authors

P. Moreau· 4 shared S. Minvielle· 4 shared C. Guerin-Charbonnel· 3 shared H. Avet-Loiseau· 3 shared L. Campion· 3 shared C. Herrmann· 2 shared E. Douillard· 2 shared J. Derrien· 2 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

P. Moreau

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Chromatin accessibility combined with enhancer clusters activation mediates heterogeneous response to dexamethasone in myeloma cells

V. GABORIT, J. CRUARD, C. Guerin-Charbonnel, J. Derrien, J.-B. Alberge, E. Douillard, N. Roi, M. Devic, L. Campion, F. Westermann, P. Moreau, C. Herrmann, J. Bourdon, F. Magrangeas, S. Minvielle

The paper investigates how chromatin accessibility and enhancer clusters mediate heterogeneous responses to dexamethasone in myeloma cells, showing epigenomic changes linked to transcriptional heterogeneity.

bioRxiv · Sep 6, 2021 · PreprintCancer Biology

The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability

J. Derrien, C. Guerin-Charbonnel, V. Gaborit, L. Campion, M. Devic, E. Douillard, N. Roi, H. Avet-Loiseau, O. Decaux, T. Facon, J.-P. Mallm, R. Eils, N. C. Munshi, P. Moreau, C. Herrmann, , S. Minvielle

This study examines DNA methylation heterogeneity in multiple myeloma, linking it to transcriptomic variability and poor patient outcomes through epigenetic and structural changes.

bioRxiv · Oct 1, 2020 · PreprintCancer Biology

DNA hydroxymethylation reveals transcription regulation networks and prognostic signatures in multiple myeloma

J.-B. Alberge, F. Magrangeas, M. Wagner, S. Denie, C. Guerin-Charbonnel, L. Campion, M. Attal, H. Avet-Loiseau, T. Carell, P. Moreau, S. Minvielle, A. A. Serandour

This study analyzes DNA hydroxymethylation in multiple myeloma to identify regulation networks and prognostic signatures associated with disease progression and survival.

bioRxiv · Oct 16, 2019Cancer Biology

Genomic landscape and chronological reconstruction of driver events in multiple myeloma

F. Maura, N. Bolli, N. Angelopoulos, K. J. Dawson, D. Leongamornlert, I. Martincorena, T. J. Mitchell, A. Fullam, S. Gonzalez, R. Szalat, B. Rodriguez-Martin, M. K. Samur, D. Glodzik, M. Roncador, M. Fulciniti, , P. J. Campbell

This study reconstructs the genomic evolution of multiple myeloma by analyzing 67 genomes from 30 patients and public datasets, identifying 7 subgroups defined by distinct driver mutations and chronological patterns of genomic events.

bioRxiv · Aug 12, 2018Cancer Biology